이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CombiGene 대차 대조표 상태

재무 상태 기준 확인 5/6

CombiGene 의 총 주주 지분은 SEK102.3M 이고 총 부채는 SEK0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 SEK108.5M 및 SEK6.2M 입니다.

주요 정보

부채 비율

SEK 0

부채

이자 보상 비율	n/a
현금	SEK 83.55m
주식	SEK 94.70m
총 부채	SEK 5.96m
총 자산	SEK 100.65m

최근 재무 상태 업데이트

Is CombiGene (STO:COMBI) In A Good Position To Invest In Growth?

Oct 12

We Think CombiGene (STO:COMBI) Can Afford To Drive Business Growth

Feb 07

Recent updates

재무 상태 분석

단기부채: COMBI 의 단기 자산 ( SEK91.8M )이 단기 부채( SEK6.2M ).

장기 부채: COMBI 의 단기 자산( SEK84.7M )은 장기 부채( SEK-1,000.0 ).

부채 대 자본 내역 및 분석

부채 수준: COMBI 부채가 없습니다.

부채 감소: COMBI 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: COMBI 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: COMBI 0.8 1.7 0.8 % 매년.

CombiGene 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Is CombiGene (STO:COMBI) In A Good Position To Invest In Growth?

We Think CombiGene (STO:COMBI) Can Afford To Drive Business Growth

Recent updates

Second quarter 2024 earnings released: kr0.38 loss per share (vs kr0.32 loss in 2Q 2023)

Combigene AB (Publ) Appoints Annika Ericsson as New Chief Scientific Officer

CombiGene AB (publ) Approves Election of Marcus Isaksson as Board Member

First quarter 2024 earnings released: kr0.72 loss per share (vs kr0.74 loss in 1Q 2023)

CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Full year 2023 earnings released: kr1.80 loss per share (vs kr0.31 loss in FY 2022)

CombiGene AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.20 profit in 3Q 2022)

CombiGene AB (publ), Annual General Meeting, May 23, 2024

New major risk - Share price stability

New major risk - Market cap size

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.23 profit in 2Q 2022)

CombiGene AB (publ) Announces Chief Executive Officer Changes

First quarter 2023 earnings released: kr0.74 loss per share (vs kr0.14 loss in 1Q 2022)

Full year 2022 earnings released: kr0.31 loss per share (vs kr1.21 profit in FY 2021)

CombiGene AB (publ) to Report Q1, 2023 Results on May 12, 2023

Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)

Investor sentiment improved over the past week

CombiGene Appoints Peter Ekolind as COO

Second quarter 2022 earnings released: EPS: kr0.23 (vs kr1.18 loss in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.95 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

CombiGene AB (publ), Annual General Meeting, May 19, 2022

CombiGene's (STO:COMBI) Earnings Are Weaker Than They Seem

Combigene AB (Publ) Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study

Is CombiGene (STO:COMBI) In A Good Position To Invest In Growth?

Board Member recently bought kr100k worth of stock

New 90-day low: kr0.51

CombiGene Announces the Material from the First Large-Scale Production of CG01 Now Released for Use in the Final Parts of the Preclinical Program

We Think CombiGene (STO:COMBI) Can Afford To Drive Business Growth

CEO & Director exercised options to buy kr82k worth of stock.

Third quarter 2020 earnings released: kr0.045 loss per share

New 90-day low: kr0.61

CombiGene Announces Update on Lipodystrophy Project CGT2

New 90-day low: kr0.64

New 90-day low: kr0.80

Earnings released

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기